Phase II Study of Capecitabine, Oxaliplatin, and Cetuximab for Advanced Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is frequently resistant to chemotherapy. However, epidermal growth factor receptor (EGFR) inhibition has demonstrated activity in HCC and overcomes chemotherapy resistance in other settings. We studied the efficacy of combining the anti-EGFR antibody cetuximab with cap...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Gastrointestinal cancer research 2011-05, Vol.4 (3), p.78-83
Hauptverfasser:	Sanoff, Hanna K, Bernard, Stephen, Goldberg, Richard M, Morse, Michael A, Garcia, Reynaldo, Woods, Lynna, Moore, Dominic T, O'Neil, Bert H
Format:	Artikel
Sprache:	eng
Schlagworte:	Original Research
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!